Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

• LUNDIN J

収録刊行物

• Blood

  Blood 100 768-773, 2002

詳細情報

• CRID: 1571980075510452992
• NII論文ID: 10021256845
• データソース種別:
  • CiNii Articles